- Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDT
- The abstract summary will be available on Thursday, May 23, 2024 at ~5:00pm ET
SOUTH SAN FRANCISCO, Calif., April 24, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that interim results from the investigator-sponsored Phase 2 trial evaluating darovasertib safety and efficacy as neoadjuvant/adjuvant treatment in uveal melanoma (UM) have been selected for an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois.
Details for the oral presentation are as follows:
Session: Melanoma/ Skin Cancers
Title: A Phase 2 Safety and Efficacy Study of Neoadjuvant/Adjuvant Darovasertib for Localized Ocular Melanoma
Presenter: Anthony Joshua, M.B.B.S, Ph.D., FRACP
Abstract number: 9510
Date and Time: June 3, 2024, at 9:51 AM CDT
ASCO will publish the abstract summary on Thursday, May 23, 2024, at approximately 5:00 pm ET.